Trending
- 1 CYTODYN INC.: FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients
- 2 FDA: Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff
- 3 GEMINI THERAPEUTICS: Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients With Complement Factor H (CFH) Loss of Function Gene Variants
Newsletter
Get the latest business news and updates - delivered right to your inbox
By signing up you agree to receive email newsletters or alerts from FDA Health News. You can unsubscribe at any time.